Taking Pfizer’s Blockbuster Covid-19 Pills; PaxlovideAt the same time, federal scientists have confirmed that a rival treatment for the virus may be safer and more effective than drugs alone.

The compound can also provide a solution to the said. “Return” issuesWhen patients’ symptoms return after completing a course of paxlovide.

But more research is needed, and the Food and Drug Administration currently does not allow doctors to prescribe both drugs to patients.

The findings were published this month As a pre-print It comes from a yet-to-be-peer-reviewed, National Institutes of Health study on monkeys.

After being infected with the delta variant, some were given Paxlovid and Lagevrio – a COVID-19 antiviral drug made by Merck and Ridgeback Biotherapeutics.

Animals that received both treatments saw “reduced SARS-CoV-2 shedding and replication” early in the disease and “mild disease” compared to those that received one or the other drug. The researchers found no response between the animals that received the two drugs.

But the study’s authors cautioned that there are key questions that need attention in future human trials and trials of the two drugs. And currently, the FDA says, doctors are not allowed to prescribe Paxlovide to patients at the same time as LaGevrio.

Green light last year With the name molnupiravir, it is only Lagevrio Allowed Alternative options are “inaccessible or clinically inappropriate” by the FDA for use in patients.

Lagevrio contains additional warnings that Paxlovide does not like Accidents It can cause fertility – it should not be taken during pregnancy – and the possibility that it can lead to new, serious differences.

“So if a patient is already taking Paxlovide, an FDA-approved alternative treatment for Covid-19, they will not be eligible for LaGevrio,” agency spokesperson Chanappa Thanthibanchachai said.

Another treatment option is Eli Lilly, which contains the same type of Bebtelovimab requirementThat effectively prevented suppliers from mixing the monoclonal antibody drug with Pfizer’s pills.

“No data” on how to treat rehabilitation.

Earlier this year, South Korean researchers reported In a preliminary publication, both drugs showed “profound” improvement in mice given them.

The NIH study tested the two drugs in rhesus macaques, “the closest surrogate for humans.”

But while the study authors hypothesized that the compound might counteract the “rebound effect,” the animals in the experiment only received four days of treatment before being necropsied.

In contrast, relapses in covid patients generally have. It has been reported A few days after the individual completes the entire five-day course.

In an email, Dr. Heinz Feldman of the National Institutes of Health blamed the early end of the study on “viral kinetics”: The scientists wanted to be able to compare viral load samples before the animal’s viral load dropped too much. in different parts of the body.

“We went for peak viral replication (day 3 or 4) to better demonstrate treatment efficacy,” Feldman wrote.

The approach has sparked interest in part because the two drugs work in different ways. Paxlovide It works by Blocking the process by which the virus reproduces in the body. Lagevrio aims to fight the virus by creating it. Too many mistakes As it reproduces.

“In other viral diseases, the combination is an antiviral rule, for example, HIV and hepatitis C. The combination of antiviral drugs can increase the power and reduce the risk of exposure to resistant viruses,” said Dr. Roy Gulick, head of the Department of Infectious Diseases. at Weill Cornell Medicine, he said in an email.

Gulick is the NIH’s co-chairman. Covid-19 treatment guidelines Panel, continued publication Improved recommendations For doctors treating patients throughout the pandemic.

He also pointed to other viruses that do not require more than one antiviral, such as herpes and hepatitis B.

“Study in humans is important, but it can be challenging to improve on the 89% success rate of paxlovide,” Gulick wrote, referring to Pfizer’s. First results High risk in unvaccinated adults.

In August, the F.D.A he said. Updates Pfizer’s Emergency Use Authorization to require a clinical trial to study relapse cases. The company said it plans to study. “Retreat” For these patients, with another course of paxlovide.

So far, the NIH panel Recommendations “Currently, there is no data on the effectiveness of administering nirmatrivir with longer courses or a second dose of ritonavir,” he said for doctors treating cases of relapse.

Dr. A.S. Anthony FauciThe president Retired Chief Medical AdvisorHe is one of many Americans who have reported fighting a Covid-19 recovery.

81 year old man. He told the “NIH Record”. That he sought a second course of the drug after coming down after symptoms returned.

“I’m sicker than the first time,” Fauci said.

Leave a Reply

Your email address will not be published.